Adam Vogel, PhD, is behavioural neuroscientist and tenured Professor at The University of Melbourne, Australia. He has 20 years’ experience in the university, clinical sciences, and technology sectors. His research is focussed on assessing and treating speech, language, and swallowing dysfunction in neurodegenerative disease. This includes a focus meaningful digital biomarker development and digital therapeutics. Adam is also CEO of Redenlab Inc. a leading speech biomarker company bringing objective speech testing to industry run clinical trials. Prior to starting at Redenlab, Adam completed post-doctoral studies in Neurology at the University of Tübingen, Germany, worked as a clinical speech scientist at Great Ormond Street Hospital, London, and was a clinical scientist at Cogstate where he ran their speech analytics program.